|Trial status||Trial open for recruitment|
Interventional with experimental drug
|Phase||Trial phase 3|
|Sponsor||Institut Jules Bordet|
|Inclusion criteria||*Radiological progression RECIST 1.1 over the last 12 months*Disease progression on a PET/CT or SPECT/CT over the last 12 months*at least one lesion with hight tumour uptake on Ga-octreotate PET/CT and morphologically measurable according to RECIST1.1|
The very latest radiotherapy equipment representing one more step on the road to perfecting our cancer treatment and the precision of our patient care.